tetano
Editor, Senior Moderator
Clin J Am Soc Nephrol
. 2022 Jun 28;CJN.00830122.
doi: 10.2215/CJN.00830122. Online ahead of print.
Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2-Recovered Dialysis Patients
Philippe Attias[SUP] 1 [/SUP], Imane Azzaoui[SUP] 2 3 [/SUP], Khalil El Karoui[SUP] 4 5 [/SUP], Andréa de La Selle[SUP] 6 [/SUP], Aurélien Sokal[SUP] 2 3 [/SUP], Pascal Chappert[SUP] 6 7 [/SUP], Philippe Grimbert[SUP] 8 5 [/SUP], Ignacio Fernandez[SUP] 7 [/SUP], Magali Bouvier[SUP] 9 10 [/SUP], Chloé Samson[SUP] 5 [/SUP], Djamal Dahmane[SUP] 8 [/SUP], Philippe Rieu[SUP] 1 [/SUP], Patrice Nizard[SUP] 11 [/SUP], Slim Fourati[SUP] 9 10 [/SUP], Hamza Sakhi[SUP] 8 5 [/SUP], Matthieu Mahévas, Mondor NephroCov Study Group
Affiliations
Abstract
Background and objectives: After two doses of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients on dialysis show a defective humoral response, but a third dose could increase anti-SARS-CoV-2 spike IgG titers. Responses could be different in virus-naive and SARS-CoV-2-recovered patients on dialysis. However, characterization of memory B cell response after three doses is lacking.
Design, setting, participants, & measurements: We evaluated the dynamics of antireceptor binding domain IgG titers and antireceptor binding domain memory B cells until 6 months after two and three doses (administered within 6 months after the second dose) of mRNA vaccine in SARS-CoV-2-recovered and virus-naive dialysis populations. Results were analyzed by ordinary one-way ANOVA, the Kruskal-Wallis test, or the Wilcoxon matched-pairs test as appropriate.
Results: In total, 108 individuals (59 patients on dialysis and 49 controls) were included. In virus-naive patients on dialysis, antireceptor binding domain IgG response was quantitatively lower after two doses compared with healthy controls, but IgG titers increased by three-fold after three doses (P=0.008). In SARS-CoV-2-recovered patients on dialysis, antireceptor binding domain IgG titers after two doses were significantly higher compared with virus-naive patients on dialysis but did not significantly increase after a third dose. Regarding memory B cell response, we detected receptor binding domain-specific memory B cells at similar proportions in virus-naive patients on dialysis and vaccinated controls after two doses. Moreover, a strong receptor binding domain-specific memory B cell expansion was observed after the third dose in virus-naive patients on dialysis (5.5-fold; P<0.001). However, in SARS-CoV-2-recovered patients on dialysis, antireceptor binding domain memory B cells remained unchanged after the third dose.
Conclusions: The third dose of mRNA vaccine given within 6 months after the second dose boosts serologic and memory response in virus-naive patients but not in SARS-CoV-2-recovered patients on dialysis.
Clinical trial registry name and registration number: COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells (MEMO-COV2), NCT04402892.
Keywords: COVID-19; SARS-CoV-2; dialysis; immunology; mRNA vaccine; memory B cells.
. 2022 Jun 28;CJN.00830122.
doi: 10.2215/CJN.00830122. Online ahead of print.
Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2-Recovered Dialysis Patients
Philippe Attias[SUP] 1 [/SUP], Imane Azzaoui[SUP] 2 3 [/SUP], Khalil El Karoui[SUP] 4 5 [/SUP], Andréa de La Selle[SUP] 6 [/SUP], Aurélien Sokal[SUP] 2 3 [/SUP], Pascal Chappert[SUP] 6 7 [/SUP], Philippe Grimbert[SUP] 8 5 [/SUP], Ignacio Fernandez[SUP] 7 [/SUP], Magali Bouvier[SUP] 9 10 [/SUP], Chloé Samson[SUP] 5 [/SUP], Djamal Dahmane[SUP] 8 [/SUP], Philippe Rieu[SUP] 1 [/SUP], Patrice Nizard[SUP] 11 [/SUP], Slim Fourati[SUP] 9 10 [/SUP], Hamza Sakhi[SUP] 8 5 [/SUP], Matthieu Mahévas, Mondor NephroCov Study Group
Affiliations
- PMID: 35764393
- DOI: 10.2215/CJN.00830122
Abstract
Background and objectives: After two doses of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), patients on dialysis show a defective humoral response, but a third dose could increase anti-SARS-CoV-2 spike IgG titers. Responses could be different in virus-naive and SARS-CoV-2-recovered patients on dialysis. However, characterization of memory B cell response after three doses is lacking.
Design, setting, participants, & measurements: We evaluated the dynamics of antireceptor binding domain IgG titers and antireceptor binding domain memory B cells until 6 months after two and three doses (administered within 6 months after the second dose) of mRNA vaccine in SARS-CoV-2-recovered and virus-naive dialysis populations. Results were analyzed by ordinary one-way ANOVA, the Kruskal-Wallis test, or the Wilcoxon matched-pairs test as appropriate.
Results: In total, 108 individuals (59 patients on dialysis and 49 controls) were included. In virus-naive patients on dialysis, antireceptor binding domain IgG response was quantitatively lower after two doses compared with healthy controls, but IgG titers increased by three-fold after three doses (P=0.008). In SARS-CoV-2-recovered patients on dialysis, antireceptor binding domain IgG titers after two doses were significantly higher compared with virus-naive patients on dialysis but did not significantly increase after a third dose. Regarding memory B cell response, we detected receptor binding domain-specific memory B cells at similar proportions in virus-naive patients on dialysis and vaccinated controls after two doses. Moreover, a strong receptor binding domain-specific memory B cell expansion was observed after the third dose in virus-naive patients on dialysis (5.5-fold; P<0.001). However, in SARS-CoV-2-recovered patients on dialysis, antireceptor binding domain memory B cells remained unchanged after the third dose.
Conclusions: The third dose of mRNA vaccine given within 6 months after the second dose boosts serologic and memory response in virus-naive patients but not in SARS-CoV-2-recovered patients on dialysis.
Clinical trial registry name and registration number: COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells (MEMO-COV2), NCT04402892.
Keywords: COVID-19; SARS-CoV-2; dialysis; immunology; mRNA vaccine; memory B cells.